Last updated: September 7, 2026
Histrelin acetate is a niche gonadotropin-releasing hormone agonist marketed primarily through two long-acting implants: Supprelin LA for central precocious puberty and Vantas for advanced prostate cancer. Supprelin LA is the commercially relevant product in the United States after Vantas was discontinued. The market is small, procedure-dependent and concentrated in pediatric endocrinology. Its financial performance depends more on implant volume, reimbursement and physician administration than on broad prescription demand.
Public-company filings do not separately disclose current histrelin acetate revenue. The product remains commercially relevant because the implant provides approximately 12 months of therapy, but it faces competition from injectable leuprolide, triptorelin and other GnRH agonists.
What is histrelin acetate used for?
Histrelin acetate is a synthetic GnRH agonist. Continuous exposure suppresses pituitary secretion of luteinizing hormone and follicle-stimulating hormone, reducing downstream sex-hormone production.
| Product |
Indication |
Dosage form |
Sponsor or marketer |
FDA status |
| Supprelin LA |
Central precocious puberty in children |
Subcutaneous implant, 50 mg histrelin acetate |
Endo Pharmaceuticals |
FDA-approved |
| Vantas |
Advanced prostate cancer |
Subcutaneous implant, 50 mg histrelin acetate |
Endo Pharmaceuticals |
Discontinued in the U.S. |
| Injectable competitors |
Precocious puberty, prostate cancer and related uses |
Depot injections |
AbbVie, Tolmar, Ipsen and others |
FDA-approved products |
Supprelin LA is implanted subcutaneously in the upper arm and releases histrelin at approximately 65 micrograms per day for 12 months. The implant must be removed and replaced annually if treatment continues [1].
Vantas used the same active pharmaceutical ingredient in a prostate-cancer indication. Its commercial decline reflected limited oncology demand, competition from depot injections and the operational burden of an implant procedure.
How large is the histrelin acetate market?
The U.S. histrelin market is a specialty market rather than a mass-market pharmaceutical category. Its economic base is the population of children diagnosed with central precocious puberty and treated for one or more years.
The market has four structural characteristics:
- Annual implant replacement creates recurring revenue per treated patient.
- Treatment is concentrated among pediatric endocrinologists and specialized surgical providers.
- Reimbursement often depends on buy-and-bill, specialty pharmacy or site-of-care arrangements.
- The product competes against less invasive injections with broader provider familiarity.
Central precocious puberty is uncommon relative to general pediatric conditions. The treated population is therefore much smaller than the populations for diabetes, asthma or common hormonal disorders. The commercial value per patient is higher because the product is a branded specialty implant and requires a procedure.
No public filing provides a reliable standalone revenue series for Supprelin LA. Product-level revenue is generally included within broader specialty pharmaceutical or branded-product reporting. The absence of separately disclosed sales prevents a precise historical revenue calculation from public-company filings.
What is the financial trajectory for histrelin acetate?
The financial trajectory is best characterized as mature and stable in its core pediatric indication, with limited growth potential.
Growth drivers
Supprelin LA can retain patients for several years because treatment is often continued until an appropriate stage of pubertal development. Each replacement creates a new revenue event. The product also has a practical advantage for families seeking to avoid frequent injections.
Revenue can increase through:
- New diagnoses of central precocious puberty
- Greater recognition and referral to pediatric endocrinologists
- Continued treatment over multiple annual cycles
- Reimbursement improvements
- Retention of patients who prefer an annual implant over monthly or quarterly injections
Constraints on growth
The product has several commercial limitations:
- The addressable population is small.
- Placement and removal require a trained clinician.
- Implant-related procedures create scheduling and reimbursement friction.
- Injectable GnRH agonists are familiar to physicians and payers.
- Delayed diagnosis or insurance authorization can defer treatment.
- A single annual implant limits prescription frequency compared with monthly injectable products.
The mature product profile limits the likelihood of rapid revenue expansion. Price increases, reimbursement negotiations and patient retention are more important financial variables than unit-volume growth.
What patents protect Supprelin LA and histrelin acetate?
Histrelin acetate benefits from formulation, implant-device and delivery-system intellectual property rather than from a broad, long-lived composition-of-matter patent position.
The principal protection categories are:
| Protection category |
Commercial relevance |
| Histrelin acetate active ingredient |
Core molecule protection is no longer the primary barrier |
| Controlled-release implant |
Supports 12-month delivery and differentiates the product |
| Implant composition |
May cover polymer matrix, drug loading and release characteristics |
| Implantation and removal procedure |
Can create practical barriers but is less difficult to design around |
| Method of treatment |
May cover suppression of puberty or treatment of prostate cancer |
| Manufacturing process |
Can protect drug loading, sterilization and release-rate consistency |
The original patent estate has aged materially. Product protection has depended on formulation, device and regulatory barriers rather than an unexpired composition-of-matter monopoly. The FDA Orange Book should be used for the current patent listing and pediatric-exclusivity status associated with NDA 022058 [2].
Patent expiry does not automatically produce immediate generic entry. A competing product would need to reproduce the implant’s release profile, demonstrate pharmaceutical equivalence and address manufacturing, sterility and implantation requirements.
When does histrelin acetate lose exclusivity?
Histrelin acetate has already lost the commercial exclusivity associated with its original active ingredient. The remaining protection is more limited and may include formulation, device, regulatory and market-access barriers.
Supprelin LA received FDA approval in 2007 for central precocious puberty [3]. The pediatric indication generated regulatory exclusivity associated with the pediatric development program, but that period has expired. Vantas was approved earlier, in 2004, for advanced prostate cancer [4].
The practical exclusivity timeline is:
| Period |
Market position |
| 2004 |
Vantas approved for advanced prostate cancer |
| 2007 |
Supprelin LA approved for central precocious puberty |
| 2007 onward |
Supprelin LA becomes the principal U.S. commercial application |
| Following patent and regulatory expiry |
Entry barriers shift toward implant engineering, manufacturing and distribution |
| Current market |
Mature branded implant with limited direct competition |
The exact status of any remaining listed patent, pediatric exclusivity or regulatory exclusivity should be taken from the current FDA Orange Book record rather than historical product literature.
What is the Orange Book status of Supprelin LA?
Supprelin LA is listed in the FDA Orange Book under NDA 022058. The product is a 50-mg histrelin acetate implant administered subcutaneously [2].
An Orange Book listing can create an abbreviated new drug application pathway for a generic applicant, but implant products are more difficult to copy than conventional tablets or injections. A generic applicant would need to address:
- Active ingredient identity
- Implant dimensions and composition
- Drug-release profile
- Sterility and packaging
- Stability over the intended treatment period
- Implantation and removal characteristics
- Labeling and pharmaceutical equivalence
The product’s practical barrier is therefore higher than the barrier associated with a conventional immediate-release generic.
Are there Paragraph IV challenges to histrelin acetate?
Publicly visible Paragraph IV activity has not produced a major generic launch that materially displaced Supprelin LA in the U.S. market. The absence of a marketed generic does not mean the product is permanently protected. It indicates that the commercial opportunity has not yet justified the technical, regulatory and market-access costs of entry.
A Paragraph IV challenger would likely assess:
- Whether listed implant patents remain enforceable
- Whether the patents are invalid or not infringed
- Whether a modified implant can avoid the listed claims
- Whether the pediatric market is large enough to support development
- Whether payers would prefer the generic implant over established injections
For a small specialty market, litigation expenses can be disproportionate to expected sales. That economic calculation can deter challenges even after the strongest patents have expired.
What formulations are protected by histrelin acetate patents?
The commercially important formulation is the one-year subcutaneous implant. Its value comes from controlled release, not from the histrelin molecule alone.
Key technical barriers include:
- Uniform drug distribution through the implant matrix
- Stable release over approximately 12 months
- Maintenance of potency during storage
- Sterile manufacturing
- Consistent implant dimensions
- Predictable systemic exposure
- Reliable removal after treatment
A competing oral or injectable histrelin formulation would not necessarily substitute for Supprelin LA. The product’s market position is linked to the implant’s duration and administration model.
What patent litigation affects histrelin acetate?
Histrelin acetate has not generated the scale of public patent litigation associated with major oncology, immunology or diabetes products. The principal litigation risk is potential ANDA litigation involving an implant competitor.
The absence of high-profile recent litigation leaves the commercial risk concentrated in regulatory entry, manufacturing capability and payer adoption. If a generic applicant files a Paragraph IV certification, the NDA holder could bring suit under the Hatch-Waxman framework and obtain the statutory stay applicable to the filing.
No major current litigation event should be assumed without reviewing PACER, FDA records and the latest Orange Book data.
How does histrelin compare with leuprolide and triptorelin?
| Factor |
Histrelin acetate |
Leuprolide |
Triptorelin |
| Main pediatric use |
Central precocious puberty |
Central precocious puberty |
Central precocious puberty |
| Administration |
Annual implant |
Monthly, three-monthly or longer-acting injection |
Monthly or longer-acting injection |
| Procedure burden |
Implant and removal required |
Injection |
Injection |
| Adherence model |
High once implanted |
Requires scheduled injections |
Requires scheduled injections |
| Direct generic pressure |
Limited implant competition |
Greater across injectable products |
Moderate |
| Commercial differentiation |
Long duration and low dosing frequency |
Broad indications and established access |
Established endocrine and oncology use |
Histrelin’s strongest commercial advantage is reduced administration frequency. Its main disadvantage is the need for a minor surgical procedure. The competitive decision often depends on payer policy, physician skill, family preference and access to pediatric endocrinology.
What generic entry risks exist for Supprelin LA?
The near-term generic risk is moderate rather than high.
Low-risk factors
- Small treated population
- Implant manufacturing complexity
- Need for specialized provider adoption
- Limited public evidence of an imminent commercial generic
- Potential reimbursement and distribution barriers
Higher-risk factors
- Aging patent estate
- Lack of composition-of-matter exclusivity
- Ability to design around formulation claims
- Commercial value of annual replacement revenue
- Potential interest from specialty generic manufacturers
A successful entrant could pressure price, improve payer negotiating leverage and reduce market share for the branded product. The most likely initial effect would be price competition in selected payer channels, not immediate displacement across all pediatric practices.
What is the FDA regulatory status of histrelin acetate?
Supprelin LA is FDA-approved for the treatment of central precocious puberty in children. Vantas was FDA-approved for advanced prostate cancer but is no longer the primary commercial growth driver.
FDA approval does not eliminate post-approval obligations. The sponsor must maintain manufacturing quality, sterility, labeling, adverse-event reporting and supply continuity. For an implant, manufacturing deviations or sterile-product issues can have a larger commercial impact than they would for a standard oral product because substitution options are limited.
What licensing deals affect histrelin acetate?
Histrelin acetate has not produced a widely disclosed licensing transaction comparable with major platform drugs. Commercial rights have historically been tied to product ownership, specialty-pharma portfolios and corporate transactions rather than a visible sequence of major regional licenses.
The relevant commercial questions are:
- Which entity controls U.S. commercialization?
- Which entity manufactures the implant?
- Whether manufacturing is internal or outsourced
- Whether distribution is direct, specialty-pharmacy or buy-and-bill
- Whether rights differ by pediatric and oncology indications
Transaction-level diligence should distinguish NDA ownership, trademark ownership, manufacturing rights and sales rights. These rights do not always sit with the same legal entity.
What is the revenue exposure and commercial outlook?
Histrelin acetate is unlikely to be a material driver of a diversified pharmaceutical company’s consolidated revenue. Its financial importance is greater at the product-portfolio level than at the large-cap company level.
The commercial outlook is:
| Factor |
Outlook |
| Patient demand |
Stable niche demand |
| Unit growth |
Low to moderate |
| Pricing |
Dependent on specialty reimbursement |
| Generic threat |
Moderate over the medium term |
| Manufacturing risk |
Meaningful because of sterile implant requirements |
| Competitive risk |
Moderate from injectable GnRH agonists |
| Long-term growth |
Limited without new indications or geographic expansion |
The product can generate recurring cash flow while maintaining a defensible specialty position. It is unlikely to become a high-growth asset without a new indication, a materially broader geographic strategy or a major change in reimbursement.
Key Takeaways
- Supprelin LA is the principal commercial histrelin acetate product in the United States.
- Its main indication is central precocious puberty.
- Vantas, the prostate-cancer implant, is no longer the primary market driver.
- Revenue is recurring but concentrated in a small specialty population.
- The commercial moat comes from the annual implant, sterile manufacturing and provider workflow.
- Core molecule exclusivity has expired; remaining protection is more dependent on formulation, device and regulatory barriers.
- No major generic launch has materially disrupted the market.
- Injectable leuprolide and triptorelin are the main competitive alternatives.
- Public filings do not separately disclose a reliable current revenue series for histrelin acetate.
- The most credible market outlook is stable, mature and cash-generative, with limited volume growth and moderate medium-term generic risk.
FAQs
Is histrelin acetate still available in the United States?
Yes. Supprelin LA remains the relevant U.S. histrelin acetate product for central precocious puberty. Vantas is not the active commercial growth product.
Is Supprelin LA a biologic?
No. Histrelin acetate is a synthetic small-molecule GnRH agonist delivered through a drug implant. It is not a biologic and does not face biosimilar competition.
Can a generic company copy the Supprelin LA implant?
Potentially, but it must address implant equivalence, controlled release, sterility, stability, manufacturing consistency and implantation requirements. Those issues make entry more complex than copying a tablet.
Does histrelin acetate compete with puberty-blocking injections?
Yes. Leuprolide and triptorelin injections are the principal alternatives for central precocious puberty. Histrelin differentiates itself through annual administration.
Is histrelin acetate a high-growth pharmaceutical asset?
No. It is a mature specialty product with recurring demand and limited addressable volume. Its value is based on durable niche cash flow rather than rapid market expansion.
References
- U.S. Food and Drug Administration. (2023). Supprelin LA prescribing information.
- U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations, Orange Book.
- U.S. Food and Drug Administration. (2007). Supprelin LA approval letter and regulatory review.
- U.S. Food and Drug Administration. (2004). Vantas approval letter and regulatory review.
